{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT01614821","nct_id":"NCT01614821","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct01614821. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"PCI-32765; ibrutinib","label":"Treatment Arm","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2018-09-15","type":"ACTUAL"},"conditions":["Waldenstrom's Macroglobulinemia"],"enrollment":{"count":63,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"PCI-32765","otherNames":["ibrutinib"],"type":"DRUG"}],"last_update":"2020-01-21","lead_sponsor":"Dana-Farber Cancer Institute","official_title":"Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765), in Waldenstrom's Macroglobulinemia","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2016-09-09","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Response Rate","timeFrame":"4 years"}],"references":[{"citation":"Guijosa A, Ramirez-Gamero A, Sarosiek S, Branagan AR, von Keudell G, Treon SP, Castillo JJ. Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a pooled analysis. Blood Adv. 2025 Sep 23;9(18):4705-4715. doi: 10.1182/bloodadvances.2025016536.","pmid":"40674744","type":"DERIVED"},{"citation":"Treon SP, Meid K, Gustine J, Yang G, Xu L, Liu X, Patterson CJ, Hunter ZR, Branagan AR, Laubach JP, Ghobrial IM, Palomba ML, Advani R, Castillo JJ. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstrom Macroglobulinemia. J Clin Oncol. 2021 Feb 20;39(6):565-575. doi: 10.1200/JCO.20.00555. Epub 2020 Sep 15.","pmid":"32931398","type":"DERIVED"},{"citation":"Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL, Kanan S, Ghobrial I, Castillo JJ, Laubach JP, Hunter ZR, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba ML, Advani RH. Ibrutinib in previously treated Waldenstrom's macroglobulinemia. N Engl J Med. 2015 Apr 9;372(15):1430-40. doi: 10.1056/NEJMoa1501548.","pmid":"25853747","type":"DERIVED"}],"start_date":{"date":"2012-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia","url":"https://clinicaltrials.gov/study/NCT01614821"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct01614821"}